Search

Author/Creator Giacomini, Paul

1. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022)

Authors:
Foley, John F; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan; van der Walt, Anneke; Dwyer, Christopher; Bu...
Journal:
Lancet neurology
Issue:
Volume 21:Issue 7(2022)
Page Start:
608
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2020)

Authors:
Cree, Bruce A C; Cutter, Gary; Wolinsky, Jerry S; Freedman, Mark S; Comi, Giancarlo; Giovannoni, Gavin; Hartung, Hans-Peter; Arnold, Douglas; Kuhle, Jens; Block, Valerie; Munschauer, Frederick E; Sedel, Frédéric; Lublin, Fred D; Reingold, Stephen; Duquette, Pierre; Derfuss, Tobias; Fazekas, Franz...
Journal:
Lancet neurology
Issue:
Volume 19:Issue 12(2020)
Page Start:
988
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search